Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes
Chih-Lang Lin
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jen-Ai Hospital)
Kuan-Chou Lin
(Division of Oral and Maxillofacial Surgery, Department of Dentistry, Wan Fang Hospital, Taipei Medical University)
Jung-Min Yu
(Department of Cardiovascular Surgery, Taichung Tzu Chi Hospital)
Chia-Lun Chang
(Department of Hemato-Oncology, Wan Fang Hospital, Taipei Medical University)
Yu-Yi Lin
(Taipei Wego Private Senior High School)
Chih-Yuan Fang
(Division of Oral and Maxillofacial Surgery, Department of Dentistry, Wan Fang Hospital, Taipei Medical University)
Wan-Ming Chen
(Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University)
Szu-Yuan Wu
(Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University)
Abstract Patients with atrial fibrillation and type 2 diabetes remain at high risk of stroke despite anticoagulation and glucose-lowering treatment. We examined whether tirzepatide was associated with lower cerebrovascular risk than established glucagon-like peptide-1 receptor agonists in a retrospective cohort from a large international federated electronic health-record network. Here we show that, among 14,118 matched pairs of adults initiating tirzepatide or another glucagon-like peptide-1 receptor agonist, tirzepatide use was associated with lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and death from any cause. The absolute difference in stroke risk was 2.1 percentage points at one year, and the absolute difference in mortality was 6.2 percentage points. These observational findings support further assessment of tirzepatide as a potential option for people with both conditions, but randomized trials are required before treatment recommendations can change.
Chih-Lang Lin, Kuan-Chou Lin, Jung-Min Yu, et al. (2026). "Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes". Nature Communications. https://doi.org/10.1038/s41467-026-77047-5